omniture
TiumBio Co., Ltd.

Latest News

TiumBio Announces First Patient Dosed in Phase 2 Clinical Trial of Oral Immuno-Oncology Drug TU2218

* TU2218 is a potentially first-in-class dual inhibitor targeting transforming growth factor beta...

2024-10-04 20:00 1648

TiumBio Presents Promising Clinical Data from Phase 1 of its Hemophilia Treatment Candidate TU7710 at ISTH 2024

* TU7710, long-acting recombinant activated factor VII, demonstrated a 5 to 7 times longer half-l...

2024-06-24 20:00 1788

TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting

* Poster presentation features the interim data from an ongoing Phase 1b clinical trial of TU2218...

2024-06-01 20:00 3475

TiumBio Announces Positive Topline Data from Phase 2a Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain

* The study (NCT05138562) met its primary endpoint of change of dysmenorrhea (menstrual pain) sco...

2024-05-08 20:00 1234

TiumBio Submits CTA for Phase 1b Clinical Trial of TU7710, a Long-acting Recombinant Activated Factor VII, in Hemophilia A or B Patients

* TU7710 has the potential to be a highly effective and long-acting treatment for bleeding episod...

2024-03-26 20:00 1057

TiumBio to Initiate Phase 2 Trial of TU2218 for Cancer

* TiumBio will pursue three indications for the TU2218 combination clinical trial with pembrolizu...

2024-03-11 20:00 1435

TiumBio Secures KRW 38.5 Billion in Anticipation of Upcoming Clinical Data

* The proceeds will fund its robust clinical programs and bolster TiumBio's financial position. ...

2023-12-29 21:00 2478

TiumBio and Hansoh Pharma Announce Clinical Trial Approval of 'HS-10518/TU2670' from NMPA in China

-  Hansoh plans to develop 'TU2670 (Hansoh's code: HS-10518)' as a best-in-class novel GnRH antagon...

2023-07-05 20:00 2213